-+ 0.00%
-+ 0.00%
-+ 0.00%

Acumen Pharmaceuticals publishes corporate presentation; Alzheimer’s drug candidate sabirnetug advances in Phase 2, cash totals $117 million at Dec. 31, 2025

Reuters·03/26/2026 12:07:32

Please log in to view news